Avalyn Pharma
Seattle
About Avalyn Pharma
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $372.5M
- Funding stage: Late Stage Venture
- Last round: Series D (Jul 2025)
- Website: avalynpharma.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/avalyn-pharma-37344 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.